This site is intended for healthcare professionals
Latest drug news
  • Home
  • /
  • News
  • /
  • 2023
  • /
  • 9
  • /
  • Dupixent (dupilumab) sBLA for treatment of eosinop...

Dupixent (dupilumab) sBLA for treatment of eosinophilic esophagitis in children aged 1 to 11 years accepted for FDA priority review

Read time: 1 mins
Published:26th Sep 2023

Regeneron Pharmaceuticals, Inc. and Sanofi announced that the FDA has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Dupixent (dupilumab) to treat children aged 1 to 11 years with eosinophilic esophagitis (EoE)

The target action date for the FDA decision is January 31, 2024. Dupixent is the first and only treatment in the U.S. approved for children and adults aged 12 years and older with EoE, weighing at least 40kg.

The sBLA is supported by data from the Phase III EoE KIDS trial (Parts A and B) evaluating the efficacy and safety of Dupixent in children aged 1 to 11 with EoE. In Part A, the primary endpoint was met for the proportion of patients achieving histological disease remission (defined as peak esophageal intraepithelial eosinophil count of 6 eosinophils [eos]/high power field [hpf]) at 16 weeks for tiered dosing regimens based on body weight, compared to placebo. Part B was an active treatment extension period evaluating Dupixent for an additional 36 weeks and showed Dupixent maintained histologic remission for 52 weeks, a secondary endpoint. Dupixent also led to increases in body weight for age percentile, which was evaluated as an exploratory endpoint in Part A and a secondary endpoint in Part B.

Safety results in Parts A and B of the trial were generally consistent with the known safety profile of Dupixent in its FDA-approved EoE indication for children and adults aged 12 years and older who weigh at least 40kg. Adverse events more commonly observed (5%) with Dupixent compared to placebo were COVID-19, rash, headache, viral gastroenteritis, diarrhea and nausea.

Condition: Eosinophilic Oesophagitis
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.